Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SANA 
Sana Biotechnology Inc (SANA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: SANA (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.67
1 Year Target Price $8.67
| 4 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 125.51% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 797.47M USD | Price to earnings Ratio - | 1Y Target Price 8.67 |
Price to earnings Ratio - | 1Y Target Price 8.67 | ||
Volume (30-day avg) 8 | Beta 1.89 | 52 Weeks Range 1.26 - 5.33 | Updated Date 09/17/2025 |
52 Weeks Range 1.26 - 5.33 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.3% | Return on Equity (TTM) -109.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 810294503 | Price to Sales(TTM) - |
Enterprise Value 810294503 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.08 | Shares Outstanding 257250000 | Shares Floating 155382766 |
Shares Outstanding 257250000 | Shares Floating 155382766 | ||
Percent Insiders 7.75 | Percent Institutions 78.05 |
Upturn AI SWOT
Sana Biotechnology Inc
Company Overview
History and Background
Sana Biotechnology, Inc. was founded in 2018 and is focused on creating and delivering engineered cells as medicines for patients. Its approach focuses on controlling the expression of any gene, delivering any gene to any cell, and replacing any cell in the body.
Core Business Areas
- In Vivo Delivery: Developing delivery vehicles, including adeno-associated viruses (AAVs) and lipid nanoparticles (LNPs), to deliver genetic payloads directly to cells within the body.
- Ex Vivo Cell Engineering: Engineering cells outside the body to enhance their therapeutic properties and then transplanting them back into the patient.
- Hypoimmune Platform: Developing cells that are designed to evade the immune system, allowing for allogeneic (donor-derived) cell therapies.
Leadership and Structure
Hans Bishop serves as the CEO. Steve Harr serves as president. The company has a board of directors comprising experienced biotechnology executives and investors.
Top Products and Market Share
Key Offerings
- SGTC01 (Engineered HSCs for Hemophilia A): SGTC01 is Sana's lead ex vivo program targeting Hemophilia A using engineered hematopoietic stem cells (HSCs) to express Factor VIII. Currently in preclinical development. Competitors in Hemophilia A include BioMarin, Roche, and gene therapy companies like Spark Therapeutics (now part of Roche).
- SC291 (Engineered Allogeneic CAR T Cells for B-Cell Malignancies): SC291 represents Sana's allogeneic CAR T program using hypoimmune technology to treat B-cell malignancies. Preclinical. Competitors include Kite Pharma (Gilead), Novartis, and several other CAR T cell therapy developers.
Market Dynamics
Industry Overview
The gene and cell therapy industry is rapidly growing, driven by advancements in genetic engineering, immunology, and delivery technologies. It's characterized by high innovation, significant investment, and complex regulatory pathways.
Positioning
Sana Biotechnology is positioned as a platform company focused on developing broad enabling technologies for gene and cell therapy, particularly addressing immune rejection and delivery challenges. Its competitive advantage lies in its hypoimmune and delivery platforms.
Total Addressable Market (TAM)
The total addressable market for gene and cell therapies is estimated to reach hundreds of billions of dollars. Sana's position is to capture a significant portion by addressing key limitations in current therapies, like immunogenicity and delivery efficiency.
Upturn SWOT Analysis
Strengths
- Novel hypoimmune platform
- Diverse delivery technologies
- Experienced leadership team
- Strong financial backing
Weaknesses
- Early stage of development (preclinical)
- High R&D costs
- Dependence on technology platform success
- Limited clinical data
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in gene editing technologies
- Increasing regulatory acceptance of cell and gene therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- BMRA
- GILD
- NVS
- CRSP
Competitive Landscape
Sana's competitive advantage lies in its hypoimmune and delivery platforms, potentially enabling broader application of gene and cell therapies. However, it faces competition from established players with approved products and extensive clinical data.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by preclinical progress, platform development, and expansion of pipeline.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and successful commercialization of its therapies. Analyst estimates vary widely due to the high-risk nature of biotechnology.
Recent Initiatives: Recent initiatives include advancing lead programs (SGTC01 and SC291) towards clinical trials, expanding its manufacturing capabilities, and strengthening its intellectual property portfolio.
Summary
Sana Biotechnology is a promising early-stage biotech company with innovative platform technologies in the gene and cell therapy space. While its pipeline is still preclinical, its hypoimmune and delivery technologies address critical limitations in the field. The company faces significant risks associated with clinical development and regulatory approval, but its strong financial position provides runway for continued R&D. Investors should closely monitor clinical trial progress and competitive developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Sana Biotechnology Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is an estimate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sana Biotechnology Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2021-02-04 | President, CEO & Director Dr. Steven D. Harr M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 194 | Website https://www.sana.com |
Full time employees 194 | Website https://www.sana.com | ||
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.